Aripiprazole (Abilify)

A piperazine and quinolone derivative that is used primarily as an antipsychotic agent. It is a partial agonist of SEROTONIN RECEPTOR, 5-HT1A and DOPAMINE D2 RECEPTORS, where it also functions as a post-synaptic antagonist, and an antagonist of SEROTONIN RECEPTOR, 5-HT2A. It is used for the treatment of SCHIZOPHRENIA and BIPOLAR DISORDER, and as an adjunct therapy for the treatment of depression.

Also Known As:

Networked: 2671 relevant articles (495 outcomes, 781 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	McQuade, Robert D: 71 articles (01/2021 - 09/2002)
2.	Carson, William H: 51 articles (12/2018 - 09/2002)
3.	Baker, Ross A: 48 articles (01/2019 - 12/2008)
4.	Marcus, Ronald N: 48 articles (12/2014 - 04/2006)
5.	Correll, Christoph U: 39 articles (06/2022 - 01/2007)
6.	Kane, John M: 31 articles (06/2017 - 09/2002)
7.	Forbes, Robert A: 28 articles (07/2014 - 11/2007)
8.	Pikalov, Andrei: 28 articles (06/2011 - 05/2007)
9.	Sanchez, Raymond: 27 articles (12/2018 - 09/2005)
10.	Vieta, Eduard: 25 articles (12/2021 - 11/2004)

Related Diseases

1.	Schizophrenia (Dementia Praecox) 09/01/2010 - "This study suggested that most clinically stable outpatients with schizophrenia maintain their remission states after being switched to aripiprazole, without serious symptom aggravation and adverse events over a course of 26 weeks." 02/01/2014 - "Three studies assessed the efficacy of aripiprazole on agitation symptoms in patients with schizophrenia and for which a dose of aripiprazole between 1 and 15mg showed significant efficacy compared to placebo. " 05/01/2004 - "In multiple clinical trials, aripiprazole was effective in significantly reducing symptomatology associated with schizophrenia-related disorders compared with placebo (P < 0.05). " 01/01/2022 - "One month later, global functioning and illness insight improved; Positive and Negative Syndrome Scale score was 43 and CGI score 2. Aripiprazole LAI showed good efficacy and tolerability in an adolescent with schizophrenia. " 03/01/2020 - "The effectiveness of aripiprazole LAI was assessed through the Positive and Negative Syndrome Scale (PANSS), the Udvalg for Kliniske Undersogelser scale for side effects, the Global Assessment of Functioning and the Clinical Global Impression-Schizophrenia (CGI-SCH).Results: Upon treatment with aripiprazole LAI, patients significantly improved all the domains of PANSS (p < .05). "
2.	Psychotic Disorders (Schizoaffective Disorder) 10/01/2002 - "Most recently, aripiprazole, in early studies, appears to produce significant reductions in hPrl while maintaining therapeutic efficacy for psychosis." 07/01/2009 - "During combined treatment with mean doses of 22.9 mg of aripiprazole for 9.7 weeks, we assessed a small yet statistically not significant improvement of the psychotic disorder, whereas a marked reduction of obsessions and significant improvements of compulsions could be observed. " 01/01/2010 - "Efficacy of high-dose aripiprazole for treatment-resistant schizoaffective disorder: a case report." 11/01/2007 - "Aripiprazole 10 mg/day showed significantly greater improvements (mean change [2 x SD]) than placebo on the NPI-NH Psychosis Subscale (-6.87 [8.6] versus -5.13 [10.0]; F = 6.29, df = 1, 422, p = 0.013 by analysis of covariance [ANCOVA]); CGI-S (-0.72 [1.8] versus -0.46 [1.6]; F = 4.68, df = 1, 419, p = 0.031 [ANCOVA]); BPRS Total (-7.12 [18.4] versus -4.17 [21.6]; F = 4.72, df = 1, 399, p = 0.030 [ANCOVA]); BPRS Core (-3.07 [6.9] versus -1.74 [7.8]; F = 7.30, df = 1, 407, p = 0.007 [ANCOVA]); CMAI (-10.96 [22.6] versus -6.64 [28.6]; F = 5.23, df = 1, 410, p = 0.023 [ANCOVA]), and NPI-NH Psychosis response rate (65 versus 50%; chi(2) = 5.52, df = 1, p = 0.019 [CMH]). " 10/01/2005 - "In conclusion, aripiprazole showed similar improvements to placebo in psychotic symptoms as assessed by NPI Psychosis subscale scores, but significantly greater effects on BPRS Core and Psychosis assessments in community-living AD patients with psychosis. "
3.	Bipolar Disorder (Manic Depressive Psychosis) 02/01/2011 - "aripiprazole has proven to be an effective medication for the acute treatment of manic and mixed episodes, as well as for the prophylactic-maintenance phase of bipolar disorder in patients recovering from a manic/mixed episode. " 01/01/2009 - "Results from one of the longest bipolar maintenance trials which support aripiprazole as a prophylactic mood stabilizer, specifically against manic relapses, will be discussed as well as a post-hoc analysis that suggests efficacy for rapid cycling bipolar disorder. " 02/01/2008 - "Aripiprazole monotherapy-as dosed in this study design-was not significantly more effective than placebo in the treatment of bipolar depression at end point (Week 8)." 03/01/2021 - "Effective Treatment of 2 Childhood Depression Cases Carrying High Risk of Bipolar Disorder With Aripiprazole Monotherapy." 01/01/2021 - "Among the pharmacotherapeutic interventions, there is preliminary support for the efficacy of aripiprazole in reducing mood symptoms in people at high risk of developing bipolar disorder. "
4.	Mania (Manias) 01/01/2015 - "Factors most predictive of endpoint efficacy for aripiprazole were judgment/impulsivity at day 4 and mania at week 1. Optimal factor score improvement for outcome prediction was approximately 40% to 50%. " 09/01/2007 - "Aripiprazole was superior to placebo in reducing the severity of both mania and agitation in highly agitated patients with bipolar I disorder and showed significant antimanic activity in patients with low levels of agitation without increasing agitation. " 02/01/2014 - "Using trial data together with ancillary analyses, the European Medicines Agency concluded that aripiprazole 10 mg once daily for 12 weeks was effective in reducing symptoms of mania, but because of the high drop-out rate, efficacy over 30 weeks of treatment was not proven. " 01/01/2016 - "At 24 weeks after switching to aripiprazole, the remission rates on the Montgomery-Åsberg Depression Rating Scale (MADRS) and on both the MADRS and the Young Mania Rating Scale were increased significantly in the full sample and in the inefficacy subgroup. " 11/01/2010 - "Aripiprazole 15 or 30 mg/day was not significantly more effective than placebo in the treatment of bipolar I disorder acute mania at endpoint (Week 3). "
5.	Major Depressive Disorder (Major Depressive Disorders) 01/01/2019 - "This randomized controlled study evaluated the efficacy of low-dose (LD) and high-dose (HD) aripiprazole augmentation in major depressive disorder. " 01/01/2015 - "There is evidence to suggest that aripiprazole is beneficial in major depressive disorder and BPD with depression. " 01/01/2010 - "Adjunctive aripiprazole is beneficial for the treatment of patients with major depressive disorder but its effects on specific symptoms have not been reported. " 12/01/2011 - "To determine whether early symptom improvement with adjunctive aripiprazole in major depressive disorder (MDD) predicts overall symptom remission. " 01/01/2015 - "Efficacy of aripiprazole augmentation in Japanese patients with major depressive disorder: a subgroup analysis and Montgomery-Åsberg Depression Rating Scale and Hamilton Rating Scale for Depression item analyses of the Aripiprazole Depression Multicenter Efficacy study."

Related Drugs and Biologics

1.	Antipsychotic Agents (Antipsychotics)
2.	Risperidone (Risperdal Consta)
3.	Olanzapine (Zyprexa)
4.	Quetiapine Fumarate (Seroquel)
5.	Antidepressive Agents (Antidepressants)
6.	Haloperidol (Haldol)
7.	ziprasidone (Geodon)
8.	Clozapine (Clozaril)
9.	Paliperidone Palmitate
10.	Valproic Acid (Depakote)

Related Therapies and Procedures

1.	Therapeutics
2.	Injections
3.	Drug Therapy (Chemotherapy)
4.	Secondary Prevention
5.	Aftercare (After-Treatment)